OPKO Health, Inc. Other Non-Current Liabilities
OPKO Health, Inc. (OPK) had Other Non-Current Liabilities of $17.00 million as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-28
- 2026-06-30: Other Liabilities, Noncurrent $17.00M.
- 2026-03-31: Other Liabilities, Noncurrent $19.58M.
- 2025-12-31: Other Liabilities, Noncurrent $22.80M.
- 2025-09-30: Other Liabilities, Noncurrent $25.16M.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $17.00M 10-Q/A · filed 2026-08-28 | |
| 2026-03-31 | $19.58M 10-Q/A · filed 2026-08-28 | |
| 2025-12-31 | $22.80M 10-Q/A · filed 2026-08-28 | |
| 2025-09-30 | $25.16M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $27.81M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $30.01M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $32.84M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $36.50M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $20.32M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $21.20M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $27.19M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $25.62M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $26.84M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $27.98M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $27.37M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $22.55M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $16.24M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $15.66M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $15.06M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $20.99M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $24.87M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $26.71M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $37.07M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $45.03M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $91.65M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $77.76M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $87.80M 10-K · filed 2021-02-18 | |
| 2019-09-30 | $111.96M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $127.75M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $78.17M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $198.97M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $183.81M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $209.44M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $233.62M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $256.42M 10-K · filed 2019-03-01 | $219.95M 10-K · filed 2018-03-01 |
| 2017-09-30 | $226.62M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $201.84M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $189.58M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $271.13M 8-K · filed 2019-01-29 | $202.48M 10-K · filed 2017-03-01 |
| 2016-09-30 | $204.09M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $224.32M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $275.81M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $292.47M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $236.48M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $408.82M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $410.17M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $50.20M 10-K · filed 2016-02-29 | $217.36M 10-K · filed 2015-02-27 |
| 2014-09-30 | $216.17M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $218.49M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $215.14M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $214.78M 10-K · filed 2015-02-27 | |
| 2013-09-30 | $234.76M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $80.60M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $79.51M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $34.17M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $32.93M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $22.87M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $22.50M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $25.44M 10-K · filed 2013-03-18 | |
| 2010-12-31 | $1.07M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |